Pharsight

Janssen Prods patents expiration

1. Edurant patents expiration

EDURANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080551 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2023

(5 months ago)

US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(1 year, 6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 JANSSEN PRODS Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(1 year, 1 month ago)

US7638522 JANSSEN PRODS Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
Apr, 2023

(5 months ago)

Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 20 May, 2011

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive patients with hiv-1 rna less than or equal to 100,000 at the start of thearpy; In combination wi...

Dosage: TABLET;ORAL

More Information on Dosage

EDURANT family patents

Family Patents

2. Olysio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7671032 JANSSEN PRODS HCV NS-3 serine protease inhibitors
May, 2025

(1 year, 7 months from now)

US9856265 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8349869 JANSSEN PRODS Macrocylic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8754106 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8741926 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US9040562 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8148399 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Sep, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9623022 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US9353103 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

Drugs and Companies using SIMEPREVIR SODIUM ingredient

Market Authorisation Date: 22 November, 2013

Treatment: Method of treating hepatitis c

Dosage: CAPSULE;ORAL

More Information on Dosage

OLYSIO family patents

Family Patents

3. Prezcobix patents expiration

PREZCOBIX's oppositions filed in EPO
PREZCOBIX Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(4 months from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(3 years from now)

US8148374 JANSSEN PRODS Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(10 months from now)

US7700645

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Jun, 2027

(3 years from now)

US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Market Authorisation Date: 29 January, 2015

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; Treatment of hiv infection in adults and pediatric patients weighing a...

Dosage: TABLET;ORAL

How can I launch a generic of PREZCOBIX before it's drug patent expiration?
More Information on Dosage

PREZCOBIX family patents

Family Patents

4. Prezista patents expiration

PREZISTA's oppositions filed in EPO
PREZISTA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(4 months from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(10 months from now)

US7700645

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Jun, 2027

(3 years from now)

Drugs and Companies using DARUNAVIR ingredient

Market Authorisation Date: 23 June, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of PREZISTA before it's drug patent expiration?
More Information on Dosage

PREZISTA family patents

Family Patents

5. Symtuza patents expiration

SYMTUZA's oppositions filed in EPO
SYMTUZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(4 months from now)

US7390791 JANSSEN PRODS Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(1 year, 6 months from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(3 years from now)

US8148374 JANSSEN PRODS Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(5 years from now)

US8754065 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

US9296769 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 JANSSEN PRODS Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 7 months ago)

US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

US10786518 JANSSEN PRODS Compositions and methods of treating HIV
Jul, 2038

(14 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 17 July, 2018

Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 i...

Dosage: TABLET;ORAL

How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage

SYMTUZA family patents

Family Patents

6. Yondelis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895557 JANSSEN PRODS Pharmaceutical formulations of ecteinascidin compounds
Jan, 2028

(4 years from now)

US8895557

(Pediatric)

JANSSEN PRODS Pharmaceutical formulations of ecteinascidin compounds
Jul, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Apr 23, 2023

Drugs and Companies using TRABECTEDIN ingredient

Market Authorisation Date: 23 October, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of YONDELIS before it's drug patent expiration?
More Information on Dosage

YONDELIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic